Published in Hypertension on April 07, 2008
Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med (2009) 2.40
Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol (2011) 1.99
Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension (2009) 1.52
ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. Am J Physiol Regul Integr Comp Physiol (2010) 1.51
Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes. Diabetes (2010) 1.48
Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension (2009) 1.41
ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther (2011) 1.32
ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol (2013) 1.19
Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol (2010) 1.11
Angiotensin-converting enzyme 2 in the brain: properties and future directions. J Neurochem (2008) 1.11
Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. Am J Physiol Renal Physiol (2011) 1.08
Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension (2013) 1.07
ACE2 activation promotes antithrombotic activity. Mol Med (2010) 1.04
Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension (2013) 0.98
Activation of the ACE2/angiotensin-(1-7)/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitors. Diabetes (2012) 0.98
Targeting the ACE2-Ang-(1-7) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure. J Mol Cell Cardiol (2010) 0.96
Angiotensin-converting enzymes and drug discovery in cardiovascular diseases. Drug Discov Today (2010) 0.96
Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept (2012) 0.93
New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens (2012) 0.93
Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension (2014) 0.93
Renin-angiotensin system in the kidney: What is new? World J Nephrol (2014) 0.92
ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep (2014) 0.92
Key developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol (2012) 0.91
Direct activation of Epac by sulfonylurea is isoform selective. Chem Biol (2011) 0.91
Angiotensin-converting enzyme 2: the first decade. Int J Hypertens (2011) 0.90
Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clin Sci (Lond) (2010) 0.89
Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction. Exp Physiol (2012) 0.86
From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Front Physiol (2014) 0.85
Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev (2012) 0.85
Short-term treatment with diminazene aceturate ameliorates the reduction in kidney ACE2 activity in rats with subtotal nephrectomy. PLoS One (2015) 0.83
Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (2014) 0.82
Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension. Int J Hypertens (2012) 0.82
Role of non-classical renin-angiotensin system axis in renal fibrosis. Front Physiol (2015) 0.81
Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. Int J Pept (2012) 0.81
Gene transfer of angiotensin-converting enzyme 2 in the nucleus tractus solitarius improves baroreceptor heart rate reflex in spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst (2011) 0.80
Angiotensin-converting enzyme 2 as a therapeutic target for heart failure. Curr Heart Fail Rep (2014) 0.79
ACE2/Ang-(1-7)/Mas axis stimulates vascular repair-relevant functions of CD34+ cells. Am J Physiol Heart Circ Physiol (2015) 0.78
New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon? Curr Hypertens Rep (2015) 0.78
ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterial hypertension in rats. Lung (2013) 0.78
The angiotensin-(1-7)/Mas receptor axis is expressed in sinoatrial node cells of rats. J Histochem Cytochem (2011) 0.78
Angiotensin II-related hypertension and eye diseases. World J Cardiol (2014) 0.78
ACE2 and Microbiota: Emerging Targets for Cardiopulmonary Disease Therapy. J Cardiovasc Pharmacol (2015) 0.77
ACE and ACE2 in kidney disease. World J Nephrol (2015) 0.76
Association of exercise training and angiotensin-converting enzyme 2 activator improves baroreflex sensitivity of spontaneously hypertensive rats. Braz J Med Biol Res (2016) 0.75
Changes in Angiotensin Receptor Distribution and in Aortic Morphology Are Associated with Blood Pressure Control in Aged Metabolic Syndrome Rats. Int J Hypertens (2016) 0.75
Expression of MAS1 in breast cancer. Cancer Sci (2015) 0.75
Structural determinants for binding to angiotensin converting enzyme 2 (ACE2) and angiotensin receptors 1 and 2. Front Pharmacol (2015) 0.75
New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option? Exp Biol Med (Maywood) (2016) 0.75
Downregulation of Renal G Protein-Coupled Receptor Kinase Type 4 Expression via Ultrasound-Targeted Microbubble Destruction Lowers Blood Pressure in Spontaneously Hypertensive Rats. J Am Heart Assoc (2016) 0.75
The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res (2017) 0.75
Interactions with aromatic rings in chemical and biological recognition. Angew Chem Int Ed Engl (2003) 5.63
Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med (2009) 2.40
Circulating angiotensin II and dietary salt: converging signals for neurogenic hypertension. Curr Hypertens Rep (2007) 2.23
Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol (2006) 2.17
Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest (2009) 2.13
Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol (2008) 2.11
Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol (2011) 1.99
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood (2013) 1.98
Brain microglial cytokines in neurogenic hypertension. Hypertension (2010) 1.97
Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives. Br J Pharmacol (2003) 1.93
Ancient evolutionary origin of diversified variable regions demonstrated by crystal structures of an immune-type receptor in amphioxus. Nat Immunol (2006) 1.92
Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol (2005) 1.85
Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation (2008) 1.72
Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med (2013) 1.71
Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res (2009) 1.71
The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med (2010) 1.64
Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension (2007) 1.63
Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics (2003) 1.62
Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury. Exp Physiol (2011) 1.61
Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ Res (2008) 1.59
Angiotensin-(1-7) counterregulates angiotensin II signaling in human endothelial cells. Hypertension (2007) 1.58
ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics (2006) 1.58
Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. Hypertension (2011) 1.48
Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol (2013) 1.48
Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension (2009) 1.41
Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension (2008) 1.37
Endothelial dysfunction and elevated blood pressure in MAS gene-deleted mice. Hypertension (2008) 1.37
NAD(P)H oxidase inhibition attenuates neuronal chronotropic actions of angiotensin II. Circ Res (2005) 1.36
ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol (2007) 1.36
Noninvasive optical imaging of staphylococcus aureus bacterial infection in living mice using a Bis-dipicolylamine-Zinc(II) affinity group conjugated to a near-infrared fluorophore. Bioconjug Chem (2008) 1.34
Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol (2006) 1.34
Optical imaging of mammary and prostate tumors in living animals using a synthetic near infrared zinc(II)-dipicolylamine probe for anionic cell surfaces. J Am Chem Soc (2010) 1.34
Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem (2005) 1.32
Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension (2009) 1.32
ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Mol Ther (2011) 1.32
Resolution of the novel immune-type receptor gene cluster in zebrafish. Proc Natl Acad Sci U S A (2004) 1.30
Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens (2007) 1.30
ACE2: A novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol (2005) 1.28
Genetic deletion of the angiotensin-(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int (2009) 1.27
Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics (2004) 1.25
Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension (2006) 1.24
Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain. Am J Physiol Heart Circ Physiol (2007) 1.23
Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. Exp Physiol (2009) 1.20
Macrophage migration inhibitory factor: an intracellular inhibitor of angiotensin II-induced increases in neuronal activity. J Neurosci (2004) 1.20
ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clin Sci (Lond) (2007) 1.20
A current view of brain renin-angiotensin system: Is the (pro)renin receptor the missing link? Pharmacol Ther (2009) 1.19
Molecular mechanisms involved in the angiotensin-(1-7)/Mas signaling pathway in cardiomyocytes. Hypertension (2008) 1.19
Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol (2003) 1.19
Brain cytokines as neuromodulators in cardiovascular control. Clin Exp Pharmacol Physiol (2009) 1.18
Angiotensin-(1-7): beyond the cardio-renal actions. Clin Sci (Lond) (2013) 1.17
Novel mechanism of brain soluble epoxide hydrolase-mediated blood pressure regulation in the spontaneously hypertensive rat. FASEB J (2005) 1.17
Characterization of a functional (pro)renin receptor in rat brain neurons. Exp Physiol (2008) 1.16
Perinatal loss of Nkx2-5 results in rapid conduction and contraction defects. Circ Res (2008) 1.16
Involvement of the brain (pro)renin receptor in cardiovascular homeostasis. Circ Res (2010) 1.14
Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant (2009) 1.14
Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res (2013) 1.13
Mechanisms of antigen receptor evolution. Semin Immunol (2004) 1.13
Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling and heart failure. Mol Cell Biol (2010) 1.12
Cloning and characterization of a secreted form of angiotensin-converting enzyme 2. Regul Pept (2004) 1.12
Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo. J Med Chem (2009) 1.11
Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol (2010) 1.11
Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J Immunol (2011) 1.10
An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. Hypertension (2011) 1.10
Sodium hyaluronate accelerates the healing process in tooth sockets of rats. Arch Oral Biol (2008) 1.09